BeiGene doses first patient in phase 1b/2 trial of ZW25 in HER2-positive breast cancer and GEA
Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone. “To date, ZW25 has demonstrated promising activity in